148 related articles for article (PubMed ID: 26558270)
1. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.
Urabe S; Isomoto H; Ishida T; Maeda K; Inamine T; Kondo S; Higuchi N; Sato K; Uehara R; Yajima H; Machida H; Chen CC; Fukuda Y; Takeshima F; Nakao K; Tsukamoto K
Biomed Res Int; 2015; 2015():416838. PubMed ID: 26558270
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease.
Laserna-Mendieta EJ; Salvador-Martín S; Arias A; López-Cauce B; Marín-Jiménez I; Menchén LA; Marín-Rubio L; Ontañón Rodríguez J; López-Fernández LA; Lucendo AJ
Biomed Pharmacother; 2023 Mar; 159():114225. PubMed ID: 36621146
[TBL] [Abstract][Full Text] [Related]
4. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
[TBL] [Abstract][Full Text] [Related]
6. Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.
Medrano LM; Taxonera C; González-Artacho C; Pascual V; Gómez-García M; Barreiro-de Acosta M; Pérez-Calle JL; Bermejo F; López-Sanromán A; Martín Arranz D; Gisbert JP; Mendoza JL; Martín J; Núñez C; Urcelay E
Mediators Inflamm; 2015; 2015():318207. PubMed ID: 26339133
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
8. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
[TBL] [Abstract][Full Text] [Related]
10. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease.
Park SH; Hong M; Lee HS; Ye BD; Hwang SW; Jung S; Baek J; Moon JW; Kim BM; Oh SH; Kim KM; Lee I; Im CN; Liu J; McGovern DPB; Yang SK; Song K
J Gastroenterol Hepatol; 2019 Dec; 34(12):2118-2125. PubMed ID: 31039275
[TBL] [Abstract][Full Text] [Related]
11. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment.
Andreou NP; Legaki E; Dovrolis N; Boyanov N; Georgiou K; Gkouskou K; Gazouli M
Dig Liver Dis; 2021 May; 53(5):574-580. PubMed ID: 33339749
[TBL] [Abstract][Full Text] [Related]
12. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
[TBL] [Abstract][Full Text] [Related]
13. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Steenholdt C; Enevold C; Ainsworth MA; Brynskov J; Thomsen OØ; Bendtzen K
Aliment Pharmacol Ther; 2012 Oct; 36(7):650-9. PubMed ID: 22860894
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
[TBL] [Abstract][Full Text] [Related]
16. The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
Yu Q; Wang L; Zhang S; Feng T; Li L; Chen B; Chen M
Blood Transfus; 2016 Sep; 14(5):460-4. PubMed ID: 27136434
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
18. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
Feng T; Chen B; Li L; Huang S; Ben-Horin S; Qiu Y; Feng R; Li M; Mao R; He Y; Zeng Z; Zhang S; Chen M
Inflamm Bowel Dis; 2017 Oct; 23(10):1817-1824. PubMed ID: 28644181
[TBL] [Abstract][Full Text] [Related]
19. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
[TBL] [Abstract][Full Text] [Related]
20. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.
Sherlock ME; Walters T; Tabbers MM; Frost K; Zachos M; Muise A; Pope E; Griffiths AM
J Pediatr Gastroenterol Nutr; 2013 May; 56(5):512-8. PubMed ID: 23274341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
